8 results
Mechanism of Action for Common Diabetes Medications

 • SGLT2i (Dapagliflozin)
 • TZD (Pioglitazone)
 • Biguanides (Metformin)
Action for Common Diabetes ... GLP-1 Receptor Agonists ... • DPP4i / Gliptins ... #Medications #pharmacology ... pathophysiology #endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
- Pharmacology ... GLP-I receptor agonist ... failure Common Side Effects ... #Summary #DM2 #diabetes ... #endocrinology
DPP4 Inhibitors - Normal and Renal Dosing

Increase Incretins (GLP-I & GIP) -> Stimulates Insulin, Inhibits Glucagon
titrate up to effects ... only few side effects ... Renal #Dosing #Pharmacology ... #Management #Diabetes ... #DM2 #Endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
Common side effects ... very similar to DPP4s ... #Pharmacology #Dosing ... #Diabetes #DM2 ... #Endocrinology
Pituitary Mass Effects - Pathogenesis and Clinical Findings
 • Pituitary turnors are almost always a benign
Pituitary Mass Effects ... Pituitary adenomas ... Signs / Symptoms ... Hyperprolactinemia • Diabetes ... #SideEffects #endocrinology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... Sulfonylurea, TZD, DPP ... GLP-1 receptor agonist ... #Medications #pharmacology ... comparison #table #endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
GLP-1 Receptor Agonists ... - Pharmacology ... #Pharmacology # ... Summary #DM2 #diabetes ... #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
First Oral GLP-1 Agonist ... empagliflozin and DPP4 ... #semaglutide #Diabetes ... #Pharmacology # ... Endocrinology